Display options
Cite
Wilson TR, Yu J, Lu X, et al. The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. NPJ Breast Cancer. 2016;2:16022doi: 10.1038/npjbcancer.2016.22.
Wilson, T. R., Yu, J., Lu, X., Spoerke, J. M., Xiao, Y., O'Brien, C., Savage, H. M., Huw, L. Y., Zou, W., Koeppen, H., Forrest, W. F., Fridlyand, J., Fu, L., Tam, R., Schleifman, E. B., Sumiyoshi, T., Molinero, L., Hampton, G. M., O'Shaughnessy, J. A., & Lackner, M. R. (2016). The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. NPJ breast cancer, 216022. https://doi.org/10.1038/npjbcancer.2016.22
Wilson, Timothy R, et al. "The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population." NPJ breast cancer vol. 2 (2016): 16022. doi: https://doi.org/10.1038/npjbcancer.2016.22
Wilson TR, Yu J, Lu X, Spoerke JM, Xiao Y, O'Brien C, Savage HM, Huw LY, Zou W, Koeppen H, Forrest WF, Fridlyand J, Fu L, Tam R, Schleifman EB, Sumiyoshi T, Molinero L, Hampton GM, O'Shaughnessy JA, Lackner MR. The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. NPJ Breast Cancer. 2016 Jul 13;2:16022. doi: 10.1038/npjbcancer.2016.22. eCollection 2016. PMID: 28721382; PMCID: PMC5515335.
Copy Download .nbib Format: NLM
Share it on

NPJ Breast Cancer. 2016 Jul 13;2:16022. doi: 10.1038/npjbcancer.2016.22. eCollection 2016.

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.

NPJ breast cancer

Timothy R Wilson, Jianjun Yu, Xuyang Lu, Jill M Spoerke, Yuanyuan Xiao, Carol O'Brien, Heidi M Savage, Ling-Yuh Huw, Wei Zou, Hartmut Koeppen, William F Forrest, Jane Fridlyand, Ling Fu, Rachel Tam, Erica B Schleifman, Teiko Sumiyoshi, Luciana Molinero, Garret M Hampton, Joyce A O'Shaughnessy, Mark R Lackner

Affiliations

  1. Department of Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
  2. Department of Biostatistics, Genentech Inc., South San Francisco, CA, USA.
  3. Department of Research Pathology, Genentech Inc., South San Francisco, CA, USA.
  4. Department of Bioinformatics, Genentech Inc., South San Francisco, CA, USA.
  5. US Oncology, Dallas, TX, USA.
  6. Baylor Sammons Cancer Center, Dallas, TX, USA.
  7. Texas Oncology, Dallas, TX, USA.

PMID: 28721382 PMCID: PMC5515335 DOI: 10.1038/npjbcancer.2016.22

Abstract

Breast cancer is a heterogeneous disease and patients are managed clinically based on ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular landscape of high-risk breast cancer patients enrolled onto an adjuvant chemotherapy study to understand how disease subsets and tumor immune status impact survival. DNA and RNA were extracted from 861 breast cancer samples from patients enrolled onto the United States Oncology trial 01062. Samples were characterized using multiplex gene expression, copy number, and qPCR mutation assays. HR

Conflict of interest statement

T.R.W., Y.X., J.S., J.Y., X.L., C.O.B., H.S., L.Y.H., W.Z., H.K., W.F.F., L.F., R.T., J.F., E.S., T.S., L.M., G.H. and M.R.L. are employed by Genentech and have equity in Roche. The remaining author d

References

  1. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
  2. J Clin Invest. 2011 Jul;121(7):2750-67 - PubMed
  3. J Clin Oncol. 2009 Mar 10;27(8):1160-7 - PubMed
  4. J Clin Oncol. 2012 Jan 1;30(1):11-8 - PubMed
  5. Nature. 2000 Aug 17;406(6797):747-52 - PubMed
  6. Genes Cancer. 2013 Nov;4(11-12):419-26 - PubMed
  7. Nature. 2002 Jan 31;415(6871):530-6 - PubMed
  8. Clin Cancer Res. 2013 Oct 1;19(19):5533-40 - PubMed
  9. PLoS One. 2014 Feb 10;9(2):e88401 - PubMed
  10. Clin Cancer Res. 2015 Oct 1;21(19):4305-11 - PubMed
  11. Breast Cancer Res. 2008;10(4):R65 - PubMed
  12. JAMA Oncol. 2015 Jul;1(4):448-54 - PubMed
  13. Cancer Res. 2005 Dec 1;65(23):10783-93 - PubMed
  14. Clin Cancer Res. 2009 Apr 1;15(7):2472-8 - PubMed
  15. Nature. 2012 Jun 10;486(7403):353-60 - PubMed
  16. Breast Cancer Res Treat. 2011 Jul;128(2):315-26 - PubMed
  17. J Biol Chem. 2001 Nov 9;276(45):42259-67 - PubMed
  18. Clin Cancer Res. 2014 Jan 15;20(2):511-21 - PubMed
  19. J Clin Oncol. 2015 Mar 1;33(7):701-8 - PubMed
  20. Nature. 2012 Apr 04;486(7403):395-9 - PubMed
  21. Onco Targets Ther. 2014 Apr 10;7:543-52 - PubMed
  22. N Engl J Med. 2004 Dec 30;351(27):2817-26 - PubMed
  23. Clin Cancer Res. 2015 Apr 1;21(7):1688-98 - PubMed
  24. Nature. 2012 Apr 18;486(7403):346-52 - PubMed
  25. Nature. 2012 Oct 4;490(7418):61-70 - PubMed
  26. Nature. 2012 May 16;486(7403):400-4 - PubMed
  27. Breast Cancer Res Treat. 2014 Nov;148(2):315-25 - PubMed
  28. PLoS One. 2012;7(12):e51153 - PubMed
  29. J Clin Oncol. 2010 Jan 1;28(1):105-13 - PubMed
  30. Oncogenesis. 2013 Dec 23;2:e83 - PubMed
  31. Breast Cancer Res. 2012 Oct 26;14(5):R138 - PubMed
  32. Ann Oncol. 2014 Aug;25(8):1544-50 - PubMed
  33. PLoS One. 2014 Mar 21;9(3):e90761 - PubMed
  34. Nature. 2012 Jun 20;486(7403):405-9 - PubMed
  35. N Engl J Med. 2002 Dec 19;347(25):1999-2009 - PubMed
  36. Ann Oncol. 2014 Feb;25(2):366-71 - PubMed
  37. J Clin Oncol. 2014 Sep 20;32(27):2951-8 - PubMed
  38. J Clin Oncol. 2015 Mar 20;33(9):983-91 - PubMed
  39. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 - PubMed
  40. J Clin Oncol. 2010 Jun 1;28(16):2784-95 - PubMed
  41. Breast Cancer Res Treat. 2015 Jul;152(1):29-39 - PubMed

Publication Types